Gemini Therapeutics (NASDAQ:GMTX) Stock Price Down 0% - Time to Sell?

Key Points

• Shares of Gemini Therapeutics (NASDAQ:GMTX) were essentially unchanged Friday at $65.95 after trading as low as $65.2550, while volume surged to 424,058 shares, a 124% increase over the average daily volume.
• The stock trades below its 200-day moving average ($76.16) but slightly above its 50-day ($64.70); the company has a market cap of about $2.86 billion and a negative P/E (-65.95), reflecting its clinical-stage status.
• Gemini is a clinical-stage biotech developing integrin-targeting therapies aimed at fibrotic diseases, with lead programs focused on chronic kidney disease and idiopathic pulmonary fibrosis.

Shares of Gemini Therapeutics, Inc. (NASDAQ:GMTX - Get Free Report) dropped 0% on Friday . The stock traded as low as $65.2550 and last traded at $65.95. Approximately 424,058 shares changed hands during trading, an increase of 124% from the average daily volume of 189,291 shares. The stock had previously closed at $65.97.

Gemini Therapeutics Stock Down 0.0%

The firm has a 50-day moving average of $64.70 and a two-hundred day moving average of $76.16. The company has a market capitalization of $2.86 billion, a PE ratio of -65.95 and a beta of -0.12.

Gemini Therapeutics Company Profile

Gemini Therapeutics NASDAQ: GMTX is a clinical‐stage biotechnology company focused on the discovery and development of integrin‐targeting therapies for fibrotic diseases. Leveraging a proprietary antibody discovery platform, Gemini identifies and optimizes highly selective inhibitors of integrin subunits that play a key role in activating transforming growth factor‐β (TGF-β), a central driver of tissue fibrosis. The company's approach is designed to block fibrotic signaling at its source, potentially offering improved safety and efficacy profiles compared with broader anti‐fibrotic agents.

Gemini's lead programs are directed toward chronic kidney disease and idiopathic pulmonary fibrosis, two areas with significant unmet medical need and limited treatment options.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.